The DEVICE Act of 2025 amends the Federal Food, Drug, and Cosmetic Act to tighten how manufacturers report device design changes and reprocessing instructions. It also creates a new rule set for communications to foreign health care providers and adds rapid assessment tests to ensure proper reprocessing of reusable devices.
The bill requires advance written notice to the FDA before changes are made and mandates quick, documented communications when devices or their safety issues are discussed abroad. Finally, it tasks the FDA with developing a list of rapid tests and enforcing data requirements tied to those tests.
At a Glance
What It Does
The bill requires written notice to the FDA before any design change or reprocessing-instruction change to a device marketed in interstate commerce. It also mandates written notice within 5 days to the Secretary for certain foreign communications about device design changes, reprocessing, or safety concerns. In addition, it inserts rapid assessment tests for reusable devices into the device definition and establishes data and usage instruction requirements for those tests, to be regulated by the Secretary.
Who It Affects
Device manufacturers and their affiliates, FDA/Secretary staff, health care providers with reprocessing protocols, and foreign health care providers who receive device-related communications.
Why It Matters
These changes improve traceability of design and reprocessing changes, standardize cross-border communications, and push for validated reprocessing methods, potentially improving patient safety and transparency for regulators and providers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The DEVICE Act of 2025 makes four core changes to the current framework governing medical devices. First, it requires manufacturers to give the FDA advance written notice before they change a device’s design or its reprocessing instructions for devices sold across state lines.
The statute also ties noncompliance to adulteration penalties under existing law. Second, it adds a new requirement that manufacturers must notify the FDA within five calendar days after making certain communications to foreign health care providers about device design changes, reprocessing protocols, or safety concerns, including communications disseminated by affiliates.
Third, the bill broadens the device definition to include rapid assessment tests that ensure proper reprocessing of reusable devices and defines what constitutes a reusable device. Finally, it tasks the FDA with creating an initial list of rapid assessment tests within a year and requires that any notification under a specific clearance process include instructions for use and validation data for those tests; enforcement begins once the list is published.
These changes are designed to improve safety oversight, ensure clearer and faster cross-border communications, and standardize reprocessing validation across the industry.
The Five Things You Need to Know
The bill requires written FDA notice before any design or reprocessing change to a device marketed interstate.
A new reporting requirement (510(r)/(s)) applies to redesigns and foreign communications about devices.
Communications to foreign health care providers must be reported to the FDA within 5 days of dissemination.
Rapid assessment tests for reusable devices are added to the device definitions and must be accompanied by use instructions and validation data.
The FDA will publish an initial list of rapid tests within 1 year, and enforcement applies to tests listed in that initial list.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short Title
Establishes the formal name: DISCLOSURE; and ENCOURAGEMENT of VERIFICATION, INNOVATION, CLEANING, and EFFICIENCY Act of 2025 (DEVICE Act of 2025). It designates the act’s intended scope and purpose.
Reporting Requirement for Design and Reprocessing Changes
Amends 501 to add a penalty linkage for noncompliance with design change reporting (via 510(r)). It also adds a new 510(r) requirement: manufacturers must provide written notice to the Secretary before making design changes or changing reprocessing instructions for devices marketed in interstate commerce.
Reporting Requirement for Communications to Foreign Health Care Providers
Adds new subsections to 501 and 510 to require written notices within 5 days after any communication to foreign health care providers about device design changes, reprocessing, or safety concerns. Defines an affiliate relationship and broad dissemination criteria for coverage.
Rapid Assessment Tests for Reprocessing
Incorporates rapid assessment tests for proper reprocessing of reusable devices into the device definition. Defines reusable devices and sets up a regulatory framework for listing these tests, requiring that instructions for use and validation data accompany notifications submitted for clearance. The Secretary will publish and update the list, with enforcement beginning for listed tests.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- FDA/Secretary staff gain clearer oversight and access to timely information on device changes and communications.
- Hospitals and health systems benefit from advance notice of design changes and reprocessing considerations, supporting safer device use.
- Medical device manufacturers with mature compliance programs gain clearer expectations and a formal process for reporting changes and foreign communications.
- Foreign health care providers receive timely safety communications which can inform clinical decisions and procurement.
- Patients benefit from faster safety signals and standardized reprocessing practices for reusable devices.
Who Bears the Cost
- Manufacturers and their affiliates bear the administrative costs of pre-change notifications, recordkeeping, and cross-border communications.
- Hospitals, clinics, and reprocessing facilities face higher compliance and training costs to align with new use and validation data requirements.
- Regulatory agencies incur costs to develop, manage, and update lists of rapid assessment tests and to enforce the new data requirements.
- Affiliates with foreign communications must implement timely reporting, creating additional coordination and potential data-sharing burdens.
Key Issues
The Core Tension
The central tension is balancing timely, cross-border safety communications and the administrative cost and potential regulatory risk placed on manufacturers, especially when defining “affiliates” and implementing rapid test validation—without stifling innovation or delaying beneficial device improvements.
The bill creates a framework that links device- change reporting to adulteration penalties, potentially increasing regulatory risk for noncompliant manufacturers. It foregrounds cross-border communications, but raises questions about how broadly “affiliate” relationships will be defined and how the five-day reporting window will operate across complex, multinational supply chains.
The rapid assessment tests initiative promises standardization, yet relies on the FDA to develop, validate, and maintain a list of acceptable tests, which may lag behind technological advances or yield uneven adoption across device types. The result is a tension between faster safety communications and the practical burden of heightened regulatory compliance, especially for smaller manufacturers and international affiliates.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.